How Cos. Can Prepare For Heartburn Drug Cancer Claims
By Michael Tanenbaum and Kelly Belnick (February 12, 2020, 3:48 PM EST) -- Ranitidine medications, including the Zantac brand, may produce a component that plaintiffs counsel allege causes a myriad of cancers. Coordination and consolidation of the claims emerging against the generic and branded form manufacturers is supported by all parties.
This early juncture is an ideal time for considering the likely scale and ramifications of a ranitidine multidistrict litigation. Proactive determinations regarding effective legal strategies can limit corporate exposure and risk; offering decision makers an opportunity to respond from a position of strength.
On Nov. 1, 2019, the U.S. Food and Drug Administration issued a statement advising that "low levels" of N-nitrosodimenthylamine, or...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!